A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma

被引：0
|
作者：
Soushi Ibata
Tsutomu Sato
Hiroyuki Kuroda
Yasuhiro Nagamachi
Satoshi Iyama
Akihito Fujimi
Yusuke Kamihara
Yuichi Konuma
Masahiro Yoshida
Ayumi Tatekoshi
Akari Hashimoto
Hiroto Horiguchi
Kaoru Ono
Kazuyuki Murase
Kohichi Takada
Koji Miyanishi
Masayoshi Kobune
Yasuo Hirayama
Junji Kato
机构：
[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology
[2] Steel Memorial Muroran Hospital,Gastroenterology and Hematology/Clinical Oncology, Internal Medicine
[3] Kiyota Hospital,Department of Hematology
[4] Oji General Hospital,Department of Hematology and Oncology
[5] Asahikawa Red Cross Hospital,Department of Hematology and Oncology
[6] Higashi Sapporo Hospital,Division of Internal Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Multiple myeloma; Consolidation/maintenance; Bortezomib; Lenalidomide; Dexamethasone; VRD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1041 / 1049
页数：8
相关论文
共 50 条
  • [41] Bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma: results of a phase I/II clinical trial
    Popat, R.
    Williams, C.
    Cook, M.
    Craddock, C.
    Basu, S.
    Singeri, C.
    Gurnbleton, T.
    Foot, N.
    Oakervee, H.
    Cavenagh, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 60 - 61
  • [42] Lenalidomide Maintenance Therapy in Patients with Multiple Myeloma
    Fillitz, M.
    Seebacher, A.
    Reisner, R.
    Pittermann-Hocker, E.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S90 - S90
  • [43] Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Weber, Donna
    Thomas, Sheeba K.
    Turturro, Francesco
    Shah, Nina
    Popat, Uday R.
    Nieto, Yago
    Bashir, Qaiser
    Munoz, Silvia C.
    Landry, Ashley
    Mendoza, Kathleen
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    Orlowski, Robert Z.
    BLOOD, 2015, 126 (23)
  • [44] Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
    Broijl, Annemiek
    Kersten, Marie-Jose
    Alemayehu, Wendimagegn Ghidey
    Levin, Mark-David
    de Weerdt, Okke
    Vellenga, Edo
    Meijer, Ellen
    Wittebol, Shulamit
    Tanis, Bea C.
    Cornelisse, Petra B.
    Stevens-Kroef, Marian
    Bos, Gerard M. J.
    Wijermans, Pierre W.
    Lokhorst, Henk
    Sonneveld, Pieter
    HAEMATOLOGICA, 2016, 101 (04)
  • [45] LENALIDOMIDE CONSOLIDATION THERAPY FOLLOWED BY LENALIDOMIDE MAINTENANCE AFTER FIRST LINE THERAPY FOR MULTIPLE MYELOMA
    Takezako, N.
    Sekiguchi, N.
    Miwa, A.
    HAEMATOLOGICA, 2013, 98 : 608 - 608
  • [46] Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.
    Ishida, Tadao
    Kimura, Hideo
    Kubo, Koumei
    Sunami, Kazutaka
    Ozaki, Shuji
    Takezako, Naoki
    Handa, Hiroshi
    Kosugi, Hiroshi
    Murakami, Hirokazu
    Shimizu, Kazuyuki
    BLOOD, 2015, 126 (23)
  • [47] Post-transplantation Consolidation and Maintenance Therapy with Lenalidomide for Japanese Patients with Multiple Myeloma
    Takamatsu, Hiroyuki
    Munemoto, Saori
    Murata, Ryoichi
    Terasaki, Yasushi
    Nakajima, Kenichi
    Nakao, Shinji
    ANTICANCER RESEARCH, 2013, 33 (12) : 5681 - 5685
  • [48] Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Tufail, Madiha
    Siegel, David S.
    McBride, Laura
    Bilotti, Elizabeth
    Bello, Erica
    Anand, Palka
    Olivo, Karly
    Bendarz, Urszula
    McNeill, Ann
    Vesole, David H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (03): : 186 - 190
  • [49] Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
    Rosinol, Laura
    Oriol, Albert
    Rios, Rafael
    Sureda, Anna
    Jesus Blanchard, Maria
    Teodoro Hernandez, Miguel
    Martinez-Martinez, Rafael
    Moraleda, Jose M.
    Jarque, Isidro
    Bargay, Juan
    Gironella, Mercedes
    de Arriba, Felipe
    Palomera, Luis
    Gonzalez-Montes, Yolanda
    Marti, Josep M.
    Krsnik, Isabel
    Arguinano, Jose M.
    Esther Gonzalez, Maria
    Pilar Gonzalez, Ana
    Felipe Casado, Luis
    Lopez-Anglada, Lucia
    Paiva, Bruno
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    Lahuerta, Juan-Jose
    Blade, Joan
    BLOOD, 2019, 134 (16) : 1337 - 1345
  • [50] Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial
    Muranushi, Hiroyuki
    Kanda, Junya
    Kobayashi, Masayuki
    Maeda, Takeshi
    Kitano, Toshiyuki
    Tsuji, Masaaki
    Ueda, Yasunori
    Ishikawa, Takayuki
    Nohgawa, Masaharu
    Watanabe, Mitsumasa
    Imada, Kazunori
    Moriguchi, Toshinori
    Itoh, Mitsuru
    Ohno, Hitoshi
    Yonezawa, Akihito
    Hirata, Hirokazu
    Arima, Nobuyoshi
    Asagoe, Kohsuke
    Anzai, Naoyuki
    Nagata, Kayoko
    Yasuno, Shinji
    Kuwabara, Yoshihiro
    Kitao, Hiromi
    Kim, Ihhwa
    Kawagishi, Kiyomi
    Ueshima, Kenji
    Tominari, Shinjiro
    Nakayama, Takeo
    Yamashita, Kouhei
    Takaori-Kondo, Akifumi
    HEMATOLOGY, 2022, 27 (01) : 239 - 248
12345